# OnCo record paper-cou-aa-301-abiraterone-de-bono-nejm-2011 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cou-aa-301-abiraterone-de-bono-nejm-2011" ;
  schema:name "COU-AA-301: abiraterone and increased survival in metastatic castration-resistant prostate cancer after docetaxel"@en ;
  schema:description "Abiraterone, a pill that blocks androgen synthesis throughout the body, lengthened survival in men with metastatic prostate cancer that had progressed after docetaxel, proving that the disease remains hormone-driven even when castration-resistant."@en ;
  schema:url <https://onco.cc/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1014618>, <https://pubmed.ncbi.nlm.nih.gov/21612468/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1014618> ;
  schema:datePublished "2011"^^xsd:gYear ;
  schema:author "de Bono JS, Logothetis CJ, Molina A, et al." ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:journals <https://onco.cc/journals/nejm/> .